{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose", "query": { "intervention": "Dose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50078, "total_pages": 5008, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T13:09:38.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00567086", "title": "Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "TEZAMPANEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TorreyPines Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 306, "start_date": "2006-10", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2007-12-04", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567086" }, { "nct_id": "NCT02906670", "title": "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology" ], "interventions": [ { "name": "Sym013", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-11-01", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 3, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02906670" }, { "nct_id": "NCT02203773", "title": "Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelogenous Leukemia", "Treatment Naive AML" ], "interventions": [ { "name": "Posaconazole", "type": "DRUG" }, { "name": "ABT-199", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 212, "start_date": "2014-10-06", "completion_date": "2022-06-16", "has_results": false, "last_update_posted_date": "2023-05-16", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 13, "location_summary": "Duarte, California • Sacramento, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203773" }, { "nct_id": "NCT05973773", "title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2023-12-18", "completion_date": "2027-05-27", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 9, "location_summary": "Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more", "locations": [ { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973773" }, { "nct_id": "NCT00074269", "title": "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 5, "start_date": "2003-07", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074269" }, { "nct_id": "NCT01322269", "title": "A Study of HQK-1001 in Patients With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Sickle Cell Anemia", "Sickle Cell Disorders", "Hemoglobin S Disease", "Sickling Disorder Due to Hemoglobin S" ], "interventions": [ { "name": "HQK-1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HemaQuest Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "12 Years to 60 Years" }, "enrollment_count": 52, "start_date": "2011-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 9, "location_summary": "Oakland, California • Miami, Florida • Augusta, Georgia + 6 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322269" }, { "nct_id": "NCT04583969", "title": "ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Lenzilumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 527, "start_date": "2020-10-23", "completion_date": "2022-04-22", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583969" }, { "nct_id": "NCT01308541", "title": "A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Monitored Anesthesia Care" ], "interventions": [ { "name": "arm 1", "type": "DRUG" }, { "name": "LUSEDRA", "type": "DRUG" }, { "name": "Propofol (arm 3)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2015-11-03", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 1, "location_summary": "Salt Lake City Utah, Utah", "locations": [ { "city": "Salt Lake City Utah", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01308541" }, { "nct_id": "NCT01833754", "title": "Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteoporosis" ], "interventions": [ { "name": "Romosozumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 24, "start_date": "2013-04-22", "completion_date": "2014-02-19", "has_results": true, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 5, "location_summary": "Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Orangeburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01833754" }, { "nct_id": "NCT07144254", "title": "Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteosarcoma Recurrent", "Osteosarcoma in Children", "Relapsed Osteosarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Tegavivint", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 24, "start_date": "2026-01-22", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-05T13:09:38.603Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07144254" } ] }